Abstract
Biogen Idec, under license from CV Therapeutics, is developing BG-9928, a selective oral adenosine A, receptor antagonist, for the potential treatment of congestive heart failure. By January 2003, phase II trials of BG-9928 were ongoing.
MeSH terms
-
Adenosine A1 Receptor Antagonists*
-
Animals
-
Clinical Trials as Topic
-
Diuretics / therapeutic use*
-
Heart Failure / drug therapy*
-
Humans
-
Structure-Activity Relationship
-
Xanthines / chemical synthesis
-
Xanthines / metabolism
-
Xanthines / pharmacology
-
Xanthines / therapeutic use*
Substances
-
Adenosine A1 Receptor Antagonists
-
BG 9928
-
Diuretics
-
Xanthines